March 9, 2015 | The Israeli drug development company BioLineRx reported that it raised $25 million in a NASDAQ public offering. The offering was set at $2 per American Depository Share. BioLineRx also reports positive interim results on a trial of its blood cancer drug, as well as other developments with some of its leading medical products for the treatment of skin lesions and for heart attack damage. BioLineRX was founded in 2003 and is headquartered in Jerusalem.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments